NextCure (NXTC) Projected to Post Quarterly Earnings on Thursday

NextCure (NASDAQ:NXTC) is expected to release its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect the company to announce earnings of ($2.26) per share for the quarter. Individuals may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 12, 2026 at 5:00 PM ET.

NextCure Stock Up 1.4%

NXTC stock opened at $13.04 on Thursday. NextCure has a twelve month low of $2.69 and a twelve month high of $15.74. The firm has a market cap of $45.77 million, a price-to-earnings ratio of -0.54 and a beta of 1.54. The business’s fifty day simple moving average is $12.63 and its two-hundred day simple moving average is $9.72.

Analyst Ratings Changes

Several research analysts recently commented on NXTC shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NextCure in a research note on Wednesday, January 28th. LADENBURG THALM/SH SH upgraded shares of NextCure from a “neutral” rating to a “buy” rating and set a $18.00 target price on the stock in a research note on Friday, November 7th. Finally, Wall Street Zen raised shares of NextCure to a “hold” rating in a research note on Saturday, December 13th. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, NextCure has an average rating of “Moderate Buy” and an average target price of $23.00.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP bought a new position in shares of NextCure during the fourth quarter valued at approximately $160,000. Millennium Management LLC purchased a new stake in NextCure during the fourth quarter worth $185,000. Geode Capital Management LLC boosted its position in NextCure by 18.6% during the 4th quarter. Geode Capital Management LLC now owns 23,157 shares of the company’s stock valued at $329,000 after acquiring an additional 3,636 shares in the last quarter. Renaissance Technologies LLC increased its holdings in shares of NextCure by 18.7% in the 4th quarter. Renaissance Technologies LLC now owns 33,634 shares of the company’s stock valued at $477,000 after acquiring an additional 5,300 shares during the period. Finally, Boothbay Fund Management LLC purchased a new position in shares of NextCure in the 4th quarter valued at $988,000. Hedge funds and other institutional investors own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.